查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178166

多形性膠質母細胞瘤治療的全球市場:市場規模 - 各藥物類別，各治療法，各最終用途，各地區展望，競爭策略，各市場區隔預測(～2032年)

Glioblastoma Multiforme Treatment Market Size- By Drug Class, By Treatment, By End Use - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 225 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球多形性膠質母細胞瘤治療的市場規模，預計至2032年達到60億5,000萬美元，以9.04％的年複合成長率成長。

由於研究開發的活躍，良好的法規環境，多形性膠質母細胞瘤的發生率上升等各種要素，預計市場擴大。強力的開發平台，預計在預測期間內給予市場大幅影響。

本報告提供全球多形性膠質母細胞瘤治療市場相關調查，市場動態，市場變數與展望，各藥物類別、治療方法、最終用途、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 多形性膠質母細胞瘤治療市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球多形性膠質母細胞瘤治療市場:各藥物類別(2019年～2032年(100萬美元))

  • Bevacizumab
  • Carmustine Wafers
  • Lomustine
  • Temozolomide
  • 其他

第7章 全球多形性膠質母細胞瘤治療市場:各治療法(2019年～2032年(100萬美元))

  • 化療
  • 免疫療法
  • 放射線治療
  • 手術
  • 標靶治療
  • 腫瘤治療領域(TTF)療法

第8章 全球多形性膠質母細胞瘤治療市場:各最終用途(2019年～2032年(100萬美元))

  • 門診病人手術中心
  • 診療所
  • 醫院

第9章 全球多形性膠質母細胞瘤治療市場:各地區(2019年～2032年(100萬美元))

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • Amgen, Inc.
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Amneal Pharmaceuticals
  • Arbor Pharmaceuticals, LLC
  • F. Hoffmann-La Roche
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.)
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
簡介目錄
Product Code: HLCA2229

Global Glioblastoma Multiforme Treatment Market Overview:

According to SPER Market Research, the Global Glioblastoma Multiforme Treatment Market is estimated to reach USD 6.05 billion by 2032 with a CAGR of 9.04%.

Glioblastoma multiforme (GBM) is an astrocytic-differentiated malignant tumour classified by the WHO as grade IV. The description and development of theories about these tumours have been covered in a wide range of historical records since they are among the most frequently clinically diagnosed central nervous system (CNS) oncological entry.The market is anticipated to grow as a result of a number of factors, including increased R&D, favourable regulatory settings, and the rising occurrence of glioblastoma multiforme. A strong pipeline is likely to significantly influence the glioblastoma multiforme (GBM) therapeutic market during the projected timeframe. It is estimated that the occurrence of brain tumours will drive market expansion throughout the course of the anticipated timeframe.The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. The need for a personalised treatment strategy to handle glioblastoma multiforme is anticipated to rise as a result of tumour heterogeneity and variance in patient-to-patient treatment approaches. The approval of new therapies is anticipated to lengthen the life expectancy of glioblastoma multiforme patients.

Impact of COVID-19 on the Global Glioblastoma Multiforme Treatment Market

The market for glioblastoma treatments has suffered as a result of COVID-19. During the COVID-19 pandemic, many ICU resources, including ventilators, personal protective equipment, and medical personnel, were diverted to COVID-19 cases, leading to the cessation of surgical neuro-oncology treatments. During the pandemic, there was instability in the ability to provide essential cancer patients with effective medical care. Additionally, it appears that individuals with glioblastoma are more susceptible to the COVID-19 infection, which led to the cancellation of surgeries and therapies. The worldwide glioma treatment market consequently has a significant impact on the market.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Drug Class, By Treatment, By End Use

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Amgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd

Global Glioblastoma Multiforme Treatment Market Segmentation:

By Drug Class: Based on the Drug Class, Global Glioblastoma Multiforme Treatment Market is segmented as; Bevacizumab, Carmustine Wafers, Lomustine, Temozolomide, Others.

By Treatment: Based on the Treatment, Global Glioblastoma Multiforme Treatment Market is segmented as; Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy, Tumor Treating Field (TTF) Therapy.

By End Use: Based on the End Use, Global Glioblastoma Multiforme Treatment Market is segmented as; Ambulatory Surgical Centres, Clinics, Hospitals.

By Region: North America accounted for the largest percentage in recent years. Government support for the expansion of the healthcare sector, together with increased awareness of unusual ailments, simple access to top-notch medical facilities, and kind reimbursement policies, are some of the key factors driving regional market growth. Asia Pacific is anticipated to grow at the fastest rate throughout the projection period due to a number of factors, including the introduction of temozolomide generics, an improved economy, an increase in the world's elderly population, and rising healthcare investment.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Glioblastoma Multiforme Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Glioblastoma Multiforme Treatment Market, By Drug Class, 2019-2032 (USD Million)

  • 6.1. Bevacizumab
  • 6.2. Carmustine Wafers
  • 6.3. Lomustine
  • 6.4. Temozolomide
  • 6.5. Others

7. Global Glioblastoma Multiforme Treatment Market, By Treatment, 2019-2032 (USD Million)

  • 7.1. Chemotherapy
  • 7.2. Immunotherapy
  • 7.3. Radiation Therapy
  • 7.4. Surgery
  • 7.5. Targeted Therapy
  • 7.6. Tumor Treating Field (TTF) Therapy

8. Global Glioblastoma Multiforme Treatment Market, By End Use, 2019-2032 (USD Million)

  • 8.1. Ambulatory Surgical Centers
  • 8.2. Clinics
  • 8.3. Hospitals

9. Global Glioblastoma Multiforme Treatment Market, By Region, 2019-2032 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Amgen, Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Amneal Pharmaceuticals
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Arbor Pharmaceuticals, LLC
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. F. Hoffmann-La Roche
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Karyopharm Therapeutics, Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Merck & Co., Inc.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Pfizer Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.)
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments